logo-loader
viewCellmid Limited

Cellmid expecting record sales in December quarter, shares up 15%

The company sells anti-ageing products for hair, skin and body.

growth concept shown with stairs going up
It has multiple brands and sells these products into Australia, Japan, US and China

Cellmid Ltd (ASX:CDY) expects its sales revenue to reach a record $2.2 million for the December quarter.

This is supported by a recent sales event on its Japanese television shopping channel that delivered sales revenue of $1.1 million.

Cellmid’s Jo-Ju® branded Japanese hair growth products have proven to be one of the most successful cosmetics ever on the Japanese television shopping channel.

READ: Cellmid partners with NZ pharmacies to distribute anti-ageing products

Cellmid’s CEO Maria Halasz said: “With around 50,000 QVC customers, a large number of them regulars, we have a strong following for our Jo-Ju® products in Japan.

“We intend to build on this to maximise the potential for our recently launched évolis® products in multiple sales channels in Japan.”

Switch to plastic bottles to increase profit margin

Cellmid recently changed packaging for its Jo-Ju® lotions from glass to plastic bottles.

As a result, net profit margins are expected to increase by around 10%, whilst manufacturing time reduced from seven months to as little as three months.

This, in turn, will allow better utilisation of working capital.

Smoothing out sales going forward

Major sales events, such as those on Japenese television channel QVC currently represent material components of sales revenue, resulting in significant fluctuations in quarterly sales.

Cellmid has been working towards setting up distribution in channels that deliver more even monthly sales.

Furthermore, the company has been actively building distribution in other channels and geographies to reduce reliance on sales from TV shopping.

Quick facts: Cellmid Limited

Price: 0.185 AUD

ASX:CDY
Market: ASX
Market Cap: $22.33 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cellmid Limited named herein, including the promotion by the Company of Cellmid Limited in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Cellmid is a well funded life sciences company that see a path to profitability

Cellmid (ASX:CDY) Chief Executive and Managing Director Maria Halasz sat down with Christine Corrado from Proactive Investors New York to discuss their biotech company that now has products available in the United States. Halasz telling Proactive they are about to spin out into 2...

on 05/15/2019

2 min read